1Hsueh WA, Law RE.PPARgamma and atherosclerosis: effects on cell growth and movement[J].Arterioscler Thromb Vasc Biol,2001,21(12):1891-5.
2Kao WH, Coresh J, Shuldiner AR, et al.Atherosclerosis Risk in Communities Study.Pro12Ala of the peroxisome proliferator-activated receptor-gamma2 gene is associated with lower serum insulin levels in nonobese African Americans: the Atherosclerosis Risk in Communities Study[J].Diabetes, 2003,52(6):1568-72.
3Iwata E, Yamamoto I, Motomura T, et al.The association of Pro12Ala polymorphism in PPARgamma2 with lower carotid artery IMT in Japanese[J].Diabetes Res Clin Pract,2003,62(1):55-9.
4Chen Z, Tshibashi S, Perry S, et al.Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL[J].Arterioscler Thromb Vasc Biol, 2001,21(3):372-7.
5Li AC, Brown KK, Silvestre MJ, et al.Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice[J].J Clin Invest, 2000,106(4):523-31.
6Koshiyama H, Shimono D, Kuwamura N, et al.Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes[J].J Clin Endocrinol Metab, 2001,86(7):3452-6.
7Malerod L, Sporstol M, Juvet LK, et al.Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor gamma and hepatocyte nuclear factor 4alpha[J].Biochem Biophys Res Commun, 2003,305(3):557-65.
8Kadowaki T, Hara K, Kubota N, et al.The role of PPARgamma in high-fat diet-induced obesity and insulin resistance[J].J Diabetes Complications, 2002,16(1):41-5.
9Hattori Y, Akimoto K, Kasai K.The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II[J].Biochem Biophys Res Commun,2000,273(3):1144-9.
10Maeda N, Takahashi M, Funahashi T, et al.PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein[J].Diabetes, 2001,50(9):2094-9.
